OncoMatch/Clinical Trials/NCT07023588

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Is NCT07023588 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Venetoclax for acute myeloid leukemia (aml).

Phase 2RecruitingYehui TanNCT07023588Data as of May 2026

Treatment: Venetoclax — A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: BCL2 inhibitor (venetoclax)

Prior venetoclax treatment

Lab requirements

Kidney function

creatinine clearance ≥ 50 mL/min (Cockcroft-Gault or 24-hour urine collection)

Liver function

AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemia infiltration)

Renal function with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection). Liver function with AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemia infiltration). Significant hepatic or renal dysfunction exceeding the inclusion criteria limits [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify